MRI with Gadolinium-Based Nanoparticles - Nanotechnology for Biomedical Imaging and Diagnostics - page 249

[99] Ogawa M, Regino CAs, Marcelino B, Williams M, Kosaka n, Bryant LH, Choyke pL,
Kobayashi H. new nanosized biocompatible mr contrast agents based on lysine-dendri-graft
macromolecules. Bioconjug Chem 2010; 21 :955-960.
[100] Kobayashi H, Kawamoto s, star RA, Waldmann TA, Brechbiel MW, Choyke pL.
Activated clearance of a biotinylated macromolecular mri contrast agent from the blood
pool using an avidin chase. Bioconjug Chem 2003; 14 :1044-1047.
[101] nwe K, Bernardo M, Regino CAs, Williams M, Brechbiel MW. Comparison of MRI
properties between derivatized dTpA and dOTA gadolinium-dendrimer conjugates.
Bioorg Med Chem 2010; 18 :5925-5931.
[102] Xu R, Wang Y, Wang X, Jeong e-K, parker dL, Lu Z-R. In vivo evaluation of a pamam-
cystamine-(Gd-dO3A) conjugate as a biodegradable macromolecular MRI contrast
agent. exp Biol Med 2007; 232 :1081-1089.
[103] Xu R, Kaneshiro TL, Jeong e-K, parker dL, Lu Z-R. synthesis and evaluation of
nanoglobule-cystamine-(Gd-dO3A), a biodegradable nanosized magnetic resonance
contrast agent for dynamic contrast-enhanced magnetic resonance urography. Int J
nanomed 2010; 5 :707.
[104] Wu C, Brechbiel MW, Kozak RW, Gansow OA. Metal-chelate-dendrimer-antibody
constructs for use in radioimmunotherapy and imaging. Bioorg Med Chem Lett
1994; 4 :449-454.
[105] nwe K, Milenic de, Ray GL, Kim Y-s, Brechbiel MW. preparation of cystamine core
dendrimer and antibody-dendrimer conjugates for MRI angiography. Mol pharm
2011; 9 :374-381.
[106] Lesch Hp, Kaikkonen Mu, pikkarainen JT, Yla-Herttuala s. Avidin-biotin technology
in targeted therapy. expert Opin drug deliv 2010; 7 :551-564.
[107] Zhu W, Okollie B, Bhujwalla ZM, Artemov d. pAMAM dendrimer-based contrast
agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach.
Magn Reson Med 2008; 59 :679-685.
[108] sano K, Temma T, Azuma T, nakai R, narazaki M, Kuge Y, saji H. A pre-targeting
strategy for mr imaging of functional molecules using dendritic Gd-based contrast
agents. Mol Imaging Biol 2011; 13 :1196-1203.
[109] Konda sd, Wang s, Brechbiel MW, Wiener eC. Biodistribution of a 153Gd-folate
dendrimer, generation = 4, in mice with folate-receptor positive and negative ovarian
tumor xenografts. Invest Radiol 2002; 37 :199-204.
[110] Chen W-T, Thirumalai d, shih T-F, Chen R-C, Tu s-Y, Lin C-I, Yang p-C. dynamic
contrast-enhanced folate-receptor-targeted MR imaging using a Gd-loaded peG-
dendrimer-folate conjugate in a mouse xenograft tumor model. Mol Imaging Biol
2010; 12 :145-154.
[111] swanson sd, Kukowska-Latallo JF, patri AK, Chen C, Ge s, Cao Z, Kotlyar A, east AT,
Baker JR. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific
magnetic resonance contrast enhancement. Int J nanomed 2008; 3 :201.
[112] Tan M, Wu X, Jeong e-K, Chen Q, Lu Z-R. peptide-targeted nanoglobular Gd-dOTA
monoamide conjugates for magnetic resonance cancer molecular imaging. Biomacro-
molecules 2010; 11 :754-761.
[113] Boswell CA, eck pK, Regino CAs, Bernardo M, Wong KJ, Milenic de, Choyke pL,
Brechbiel MW. synthesis, characterization, and biological evaluation of integrin αvβ3-
targeted pAMAM dendrimers. Mol pharm 2008; 5 :527-539.